Discovery of Potent and Non-Cytotoxic HDAC3- Selective Degraders Featuring a Propyl Hydrazide
作者
Stephan Lepper,Lukas Biermann,Fabian B. Kraft,Felix Feller,Kathrin Tan,Nisha Setia,Alexandra Hamacher,Linda Schäker‐Hübner,Matthias Ulrich Kassack,Finn Kristian Hansen
Histone deacetylase 3 (HDAC3) is an important therapeutic target in cancer, yet selective HDAC3 degraders remain limited. In this study, we report the development of novel class I HDAC degraders derived from the HDAC3-preferential inhibitor FL-007 . Two linker exit vectors were investigated, leading to the identification of a series of potent compounds ( 2a-d ) exhibiting low micromolar inhibition of HDAC2 and submicromolar inhibition of HDAC1 and HDAC3, together with selective HDAC3 degradation. Degradation activity was confirmed in MM.1S, HCT116, A2780-HDAC3-HiBiT, and Cal27CisR cells using immunoblotting and HiBiT/LgBiT assays, achieving Dmax values of up to 92%. Notably, these compounds showed no cytotoxicity up to 100 µM in both cancerous and non-cancerous cell lines. Selective HDAC3 degradation resulted in moderate chemosensitization of cisplatin-resistant Cal27CisR cells, in contrast to the stronger effects observed with cytotoxic HDAC inhibitors. For compound 2b , the chemosensitizing effect was associated with increased histone H3 acetylation and increased p21 expression.